Pfizer abandons plans for Asian trials of glaucoma drug, NicOx says

08/25/2008 | Reuters

NicOx announced today that its development partner Pfizer has opted to drop plans for Phase III trials in Asia of PF-03187207, a drug candidate for glaucoma and ocular hypertension. The French biotech firm said the collaboration with Pfizer will now concentrate on developing treatments for diabetic retinopathy.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR